Vascular network expansion, integrity of blood-brain interfaces, and cerebrospinal fluid cytokine concentration during postnatal development in the normal and jaundiced rat.
Blood–CSF barrier
Blood–brain barrier
Cerebrospinal fluid
Choroid plexus
Cytokines
Gunn
Jaundice
Neurovascular
Postnatal development hyperbilirubinemia
Journal
Fluids and barriers of the CNS
ISSN: 2045-8118
Titre abrégé: Fluids Barriers CNS
Pays: England
ID NLM: 101553157
Informations de publication
Date de publication:
07 Jun 2022
07 Jun 2022
Historique:
received:
01
01
2022
accepted:
20
04
2022
entrez:
7
6
2022
pubmed:
8
6
2022
medline:
10
6
2022
Statut:
epublish
Résumé
Severe neonatal jaundice resulting from elevated levels of unconjugated bilirubin in the blood induces dramatic neurological impairment. Central oxidative stress and an inflammatory response have been associated with the pathophysiological mechanism. Cells forming the blood-brain barrier and the choroidal blood-CSF barrier are the first CNS cells exposed to increased plasma levels of unconjugated bilirubin. These barriers are key regulators of brain homeostasis and require active oxidative metabolism to fulfill their protective functions. The choroid plexus-CSF system is involved in neuroinflammatory processes. In this paper, we address the impact of neonatal hyperbilirubinemia on some aspects of brain barriers. We describe physiological changes in the neurovascular network, blood-brain/CSF barriers integrities, and CSF cytokine levels during the postnatal period in normobilirubinemic animals, and analyze these parameters in parallel in Gunn rats that are deficient in bilirubin catabolism and develop postnatal hyperbilirubinemia. Gunn rats bearing a mutation in UGT1a genes were used. The neurovascular network was analyzed by immunofluorescence stereomicroscopy. The integrity of the barriers was evaluated by [ In normobilirubinemic animals, the neurovascular network expands postnatally and displays stage-specific regional variations in its complexity. Network expansion is not affected by hyperbilirubinemia. Permeability of the blood-brain and blood-CSF barriers to sucrose decreases between one- and 9-day-old animals, and does not differ between normobilirubinemic and hyperbilirubinemic rats. Cytokine profiles differ between CSF and plasma in all 1-, 9-, and 18-day-old animals. The CSF cytokine profile in 1-day-old animals is markedly different from that established in older animals. Hyperbilirubinemia perturbs these cytokine profiles only to a very limited extent, and reduces CSF immune cell infiltration triggered by systemic exposure to a bacterial lipopeptide. The data highlight developmental specificities of the blood-brain barrier organization and of CSF cytokine content. They also indicate that a direct effect of bilirubin on the vascular system organization, brain barriers morphological integrity, and inflammatory response of the choroid plexus-CSF system is not involved in the alteration of brain functions induced by severe neonatal jaundice.
Sections du résumé
BACKGROUND
BACKGROUND
Severe neonatal jaundice resulting from elevated levels of unconjugated bilirubin in the blood induces dramatic neurological impairment. Central oxidative stress and an inflammatory response have been associated with the pathophysiological mechanism. Cells forming the blood-brain barrier and the choroidal blood-CSF barrier are the first CNS cells exposed to increased plasma levels of unconjugated bilirubin. These barriers are key regulators of brain homeostasis and require active oxidative metabolism to fulfill their protective functions. The choroid plexus-CSF system is involved in neuroinflammatory processes. In this paper, we address the impact of neonatal hyperbilirubinemia on some aspects of brain barriers. We describe physiological changes in the neurovascular network, blood-brain/CSF barriers integrities, and CSF cytokine levels during the postnatal period in normobilirubinemic animals, and analyze these parameters in parallel in Gunn rats that are deficient in bilirubin catabolism and develop postnatal hyperbilirubinemia.
METHODS
METHODS
Gunn rats bearing a mutation in UGT1a genes were used. The neurovascular network was analyzed by immunofluorescence stereomicroscopy. The integrity of the barriers was evaluated by [
RESULTS
RESULTS
In normobilirubinemic animals, the neurovascular network expands postnatally and displays stage-specific regional variations in its complexity. Network expansion is not affected by hyperbilirubinemia. Permeability of the blood-brain and blood-CSF barriers to sucrose decreases between one- and 9-day-old animals, and does not differ between normobilirubinemic and hyperbilirubinemic rats. Cytokine profiles differ between CSF and plasma in all 1-, 9-, and 18-day-old animals. The CSF cytokine profile in 1-day-old animals is markedly different from that established in older animals. Hyperbilirubinemia perturbs these cytokine profiles only to a very limited extent, and reduces CSF immune cell infiltration triggered by systemic exposure to a bacterial lipopeptide.
CONCLUSION
CONCLUSIONS
The data highlight developmental specificities of the blood-brain barrier organization and of CSF cytokine content. They also indicate that a direct effect of bilirubin on the vascular system organization, brain barriers morphological integrity, and inflammatory response of the choroid plexus-CSF system is not involved in the alteration of brain functions induced by severe neonatal jaundice.
Identifiants
pubmed: 35672829
doi: 10.1186/s12987-022-00332-0
pii: 10.1186/s12987-022-00332-0
pmc: PMC9172137
doi:
Substances chimiques
Cytokines
0
Sucrose
57-50-1
Bilirubin
RFM9X3LJ49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Informations de copyright
© 2022. The Author(s).
Références
J Comp Neurol. 1970 Jan;138(1):31-47
pubmed: 5412719
Front Neurosci. 2015 Mar 13;9:80
pubmed: 25821432
Front Neurosci. 2020 Mar 20;14:244
pubmed: 32265643
J Neuroinflammation. 2012 Aug 07;9:187
pubmed: 22870891
Front Neuroendocrinol. 2011 Jan;32(1):10-24
pubmed: 20624414
Front Cell Neurosci. 2012 May 10;6:22
pubmed: 22590454
Cell. 2002 Aug 9;110(3):373-83
pubmed: 12176324
J Physiol Biochem. 2020 Nov;76(4):573-586
pubmed: 32794154
Trends Mol Med. 2016 Sep;22(9):758-768
pubmed: 27515064
Nature. 2010 Nov 25;468(7323):557-61
pubmed: 20944627
J Neurosci. 2018 Apr 4;38(14):3466-3479
pubmed: 29507144
Front Synaptic Neurosci. 2010 Sep 08;2:136
pubmed: 21423522
Sci Rep. 2018 Sep 12;8(1):13690
pubmed: 30209300
Curr Pharm Des. 2005;11(8):973-84
pubmed: 15777248
Front Neurosci. 2015 Feb 05;9:21
pubmed: 25698917
Brain Behav Immun. 2011 Feb;25(2):181-213
pubmed: 20970492
Mech Dev. 2015 Nov;138 Pt 1:26-36
pubmed: 26222953
Acta Pharmacol Sin. 2020 Nov;42(11):1942-1950
pubmed: 33558655
Neuroscience. 2013 Nov 12;252:320-5
pubmed: 23994594
Stem Cells Dev. 2006 Jun;15(3):407-21
pubmed: 16846377
Acta Neuropathol. 2018 Mar;135(3):337-361
pubmed: 29368213
J Biol Chem. 2014 Feb 21;289(8):4699-709
pubmed: 24403077
Int J Mol Sci. 2020 Dec 30;22(1):
pubmed: 33396688
J Physiol. 2001 Nov 1;536(Pt 3):841-53
pubmed: 11691876
Sci Transl Med. 2020 Feb 12;12(530):
pubmed: 32051225
Brain Behav Immun. 2013 Jan;27(1):42-53
pubmed: 22985907
Brain Res Dev Brain Res. 1993 Dec 17;76(2):197-205
pubmed: 8149586
Adv Vet Sci Comp Med. 1993;37:149-73
pubmed: 8273513
Mol Neurobiol. 2018 May;55(5):3642-3659
pubmed: 28523565
BMC Res Notes. 2013 Dec 20;6:547
pubmed: 24359685
Front Pharmacol. 2012 May 29;3:88
pubmed: 22661946
Nat Protoc. 2015 Jan;10(1):53-74
pubmed: 25502884
Front Neurosci. 2014 Dec 16;8:404
pubmed: 25565938
Fluids Barriers CNS. 2015 Mar 10;12:8
pubmed: 25793105
Neuron. 2015 Jul 15;87(2):271-96
pubmed: 26182414
Neuron. 2014 Sep 3;83(5):1117-30
pubmed: 25155955
Int J Biochem Cell Biol. 2013 Dec;45(12):2843-51
pubmed: 24144577
Mol Neurobiol. 2019 Jul;56(7):4718-4729
pubmed: 30377987
Front Pharmacol. 2012 May 18;3:89
pubmed: 22629246
Pediatr Res. 2019 Jan;85(2):191-197
pubmed: 30397278
J Physiol. 2018 Dec;596(23):5723-5756
pubmed: 29774535
Acta Neuropathol Commun. 2020 Jan 23;8(1):4
pubmed: 31973769
Front Pharmacol. 2012 Jul 13;3:131
pubmed: 22811666
J Neuroinflammation. 2017 Mar 24;14(1):64
pubmed: 28340583
PLoS One. 2011 Jan 31;6(1):e16165
pubmed: 21297965
J Neurodev Disord. 2019 Dec 16;11(1):34
pubmed: 31839002
J Neurosci. 2010 Jul 7;30(27):9038-50
pubmed: 20610738
Brain Res Dev Brain Res. 1993 Nov 19;76(1):115-30
pubmed: 8306423
Brain Res Dev Brain Res. 1996 Feb 26;91(2):200-8
pubmed: 8852370
Brain Behav Immun. 2018 May;70:166-178
pubmed: 29458193
PLoS One. 2013 Nov 01;8(11):e79073
pubmed: 24223883
Neuron. 2009 Oct 15;64(1):61-78
pubmed: 19840550
J Cereb Blood Flow Metab. 2013 Jan;33(1):146-56
pubmed: 23093067
Nat Rev Neurosci. 2015 Aug;16(8):445-57
pubmed: 26174708
Dev Cell. 2018 Apr 9;45(1):10-32
pubmed: 29634931
J Matern Fetal Neonatal Med. 2011 Oct;24 Suppl 1:154-5
pubmed: 21942616
Oxid Med Cell Longev. 2018 Nov 26;2018:1801243
pubmed: 30598724
Front Behav Neurosci. 2009 Aug 24;3:14
pubmed: 19738918
Nature. 2014 Jan 16;505(7483):407-11
pubmed: 24305053
Pediatr Neurol. 2013 Dec;49(6):431-8
pubmed: 24138949
Front Immunol. 2020 Jan 31;11:66
pubmed: 32082323
Nature. 2010 Nov 25;468(7323):562-6
pubmed: 20944625
Mol Pharm. 2013 May 6;10(5):1473-91
pubmed: 23298398
Microvasc Res. 1990 Nov;40(3):412-26
pubmed: 2084504
Neuron. 2017 May 3;94(3):500-516.e9
pubmed: 28472653
Neural Plast. 2015;2015:689404
pubmed: 26347402
Liver Int. 2017 Aug;37(8):1094-1102
pubmed: 28004508